FAF
MRNA icon

Fjarde Ap-fonden’s Moderna MRNA Stock Holding History

Fjarde Ap-fonden’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-51,930
Closed -$1.47M – 519
2025
Q1 		$1.47M Sell
51,930
-7,800
-13% -$277K 0.02% 483
2024
Q4 		$2.48M Buy
59,730
+3,300
+6% +$158K 0.03% 454
2024
Q3 		$3.77M Buy
+56,430
New +$5.18M 0.04% 404
2024
Q1 		$5.37M Buy
50,430
+2,400
+5% +$242K 0.06% 329
2023
Q4 		$4.78M Sell
48,030
-3,000
-6% -$252K 0.06% 338
2023
Q3 		$5.27M Sell
51,030
-900
-2% -$100K 0.07% 293
2023
Q2 		$6.31M Buy
51,930
+3,800
+8% +$507K 0.08% 265
2023
Q1 		$7.39M Sell
48,130
-2,800
-5% -$462K 0.1% 222
2022
Q4 		$9.15M Sell
50,930
-9,800
-16% -$1.6M 0.13% 185
2022
Q3 		$8.68M Hold
60,730
– – 0.11% 194
2022
Q2 		$8.68M Sell
60,730
-24,100
-28% -$3.44M 0.11% 194
2022
Q1 		$14.6M Sell
84,830
-3,300
-4% -$556K 0.14% 145
2021
Q4 		$22.4M Sell
88,130
-4,930
-5% -$1.44M 0.2% 100
2021
Q3 		$35.8M Sell
93,060
-11,170
-11% -$4.12M 0.33% 62
2021
Q2 		$24.5M Buy
104,230
+9,300
+10% +$1.66M 0.22% 94
2021
Q1 		$12.4M Buy
94,930
+900
+1% +$130K 0.11% 171
2020
Q4 		$9.82M Sell
94,030
-3,100
-3% -$314K 0.09% 214
2020
Q3 		$6.87M Buy
97,130
+1,300
+1% +$90.6K 0.07% 252
2020
Q2 		$6.15M Buy
+95,830
New +$5.25M 0.08% 261

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Fjarde Ap-fonden's MRNA Position: Q2 2025 in Review

Fjarde Ap-fonden sold out of Moderna (MRNA) in Q2 2025, closing a stake of 51,930 shares — an estimated $1.47M sold.

Fjarde Ap-fonden first reported a position in MRNA in Q2 2020 and held it in 19 quarters. The position peaked at $35.8M in Q3 2021. 674 funds tracked by Wall St. Rank hold MRNA as of Q2 2025.

  • Fjarde Ap-fonden reported no remaining Moderna position as of Q2 2025 after selling out during the quarter.
  • Fjarde Ap-fonden sold 51,930 Moderna shares in Q2 2025, an estimated $1.47M.
  • Fjarde Ap-fonden first reported a position in Moderna in Q2 2020 and held it in 19 quarters.
  • Fjarde Ap-fonden's Moderna position peaked at $35.8M in Q3 2021.
  • 674 funds tracked by Wall St. Rank held Moderna as of Q2 2025.

Based on Fjarde Ap-fonden's 13F filing for Q2 2025, filed 1 Aug 2025.